Back to results
US 2022/0064294 A1Published application
Antibodies to tigit
AssigneeArcus Biosciences, Inc.
InventorsKelsey Sivick GAUTHIER, Nigel Pelham Clinton WALKER, Xiaoning ZHAO, John LIPPINCOTT
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
Claims25
An anti-TIGIT antibody or antigen-binding fragment thereof that specifically binds to human TIGIT, comprising
- (a) a heavy chain variable region comprising a heavy chain (HC) complementarity determining region (CDR) 1 having at least 80% sequence identity to SEQ ID NO:
- 36, an HC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 37, and an HC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 38;
- and a light chain variable region comprising a light chain (LC) CDR1 having at least 80% sequence identity to SEQ ID NO:
- 39, an LC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 40, and an LC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 41;
- (b) a heavy chain variable region comprising an HC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 42, an HC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 43, and an HC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 44;
- and a light chain variable region comprising an LC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 45, an LC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 46, and an LC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 47;
- (c) a heavy chain variable region comprising an HC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 48, an HC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 49, and an HC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 50;
- and a light chain variable region comprising an LC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 51, an LC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 52, and an LC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 53;
- (d) a heavy chain variable region comprising an HC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 54, an HC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 55, and an HC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 56;
- and a light chain variable region comprising an LC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 57, an LC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 58, and an LC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 59;
- (e) a heavy chain variable region comprising an HC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 60, an HC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 61, and an HC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 62;
- and a light chain variable region comprising an LC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 63, an LC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 64, and an LC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 65;
- (f) a heavy chain variable region comprising an HC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 60, an HC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 66, and an HC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 67;
- and a light chain variable region comprising an LC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 63, an LC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 68, and an LC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 65;
- (g) a heavy chain variable region comprising an HC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 69, an HC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 55, and an HC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 70;
- and a light chain variable region comprising an LC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 71, an LC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 68, and an LC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 65;
- (h) a heavy chain variable region comprising an HC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 72, an HC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 73, and an HC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 67;
- and a light chain variable region comprising an LC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 63, an LC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 68, and an LC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 65;
- or
- (i) a heavy chain variable region comprising an HC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 74, an HC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 75, and an HC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 67;
- and a light chain variable region comprising an LC-CDR1 having at least 80% sequence identity to SEQ ID NO:
- 63, an LC-CDR2 having at least 80% sequence identity to SEQ ID NO:
- 68, and an LC-CDR3 having at least 80% sequence identity to SEQ ID NO:
- 65.
70 more elements
(canceled)
13-14. (canceled)
(canceled)
An anti-TIGIT antibody or antigen-binding fragment thereof that specifically binds to human TIGIT, comprising a heavy chain having an amino acid sequence comprising SEQ ID NO:
- 92 and a light chain having an amino acid sequence comprising SEQ ID NO:
- 93.
22-34. (canceled)
An anti-TIGIT antibody or antigen binding fragment thereof that binds to an epitope of human TIGIT comprising at least one of the following amino acid residues of SEQ ID NO 80:
- T55, Q56, N58, E60, D72, S80, and K82.
37-39. (canceled)
Dependencies are inferred from the claim text.